Digbi Health Expands Its Employer Offering with GLP-1 Obesity Management Integrated Across Payer, PBM, Provider and Employer
A state public health insurance trust has selected Digbi Health to manage obesity treatment costs for its municipal and teachers union workers amid rising GLP-1 drug expenses.
MOUNTAIN VIEW, Calif., December 1, 2025 /Digbi Newswire/ -- A leading public health insurance trust has selected Digbi Health to manage the escalating costs and effective utilization of GLP-1 weight-loss drugs. The partnership leverages Digbi Health's proprietary Obesity Compass to provide effective and cost-efficient treatment plans for all its members.
Due to the surge in demand for GLP-1 drugs, employers and health plans nationwide face uncertainty and significant cost increases. This partnership addresses those challenges without compromising member health.
Key highlights
- Effective cost management — The initiative launched in June as a cost-containment strategy after unsustainable growth in GLP-1 medication usage and costs.
- Prior authorization — Digbi Health oversees prior authorization for all weight management medications, using patented predictive modeling to determine the most effective and economical care modalities for members to achieve a healthy BMI.
- Holistic solution — Digbi Health leverages genetics, gut microbiome, continuous glucose monitoring and lab reports to provide personalized food and lifestyle support to all members on weight management medications, addressing underlying root causes, related comorbidities, medication side effects and, where recommended, medication tapering.
What precision biology does here
Precision Biology uses an individual's genetic makeup, gut microbiome profile and metabolic data to create highly personalized treatment plans. By analyzing that biological data it identifies the most effective dietary, lifestyle and pharmacological interventions, ensuring treatment addresses the root causes of obesity and related conditions.
As the market struggles with finding an optimal strategy for weight management and GLP-1 cost containment, we aim to set new care standards by focusing on three key areas: enhancing member experiences through integrations, using Precision Biology to more accurately identify those who need medication support, and tackling the underlying root causes, comorbidities, and side effects. We look forward to successfully collaborating with employers, health plans, benefits consultants, and PBMs to deliver personalized, effective, and affordable care.
— Ranjan Sinha, Founder and CEO, Digbi Health
Originally distributed via Business Wire.
About Digbi Health
Digbi Health is the precision biology care company unifying metabolic and inflammatory care — including obesity, cardiometabolic, gastrointestinal, and inflammatory disorders. These illnesses share a root cause: a mismatch between an individual's biology and the one-size-fits-all lifestyle guidance they've been given. Digbi combines the gut microbiome, genetics, advanced blood biomarkers, and continuous digital health data to build a unique biological profile for each individual and identify what is driving their disease. AI then personalizes lifestyle treatment and, when needed, clinical treatment, delivered through the first precision-biology AI-orchestrated national telehealth platform. Through Digbi Labs, we invest in our vision of making chronic illness optional and advancing healthspan — partnering with leading universities, pharmaceutical companies, and scientific and clinical laboratories, running distributed human trials and publishing peer-reviewed research on genetics, the gut microbiome, and the use of AI to deliver care that is safe, cost-effective, and accessible. Digbi's healthcare cost reduction is documented in multiple peer-reviewed actuarial claims studies. Digbi is accessible to 30 million individuals through more than 300 employers and health plans.
SOURCE Digbi Health
- GLP-1
- Public Sector Benefits
- Prior Authorization
- Obesity
- Cost Containment